Targeting co-inhibitory receptors or immune checkpoints such as PD-1 and CTLA-4 by antibody blockade, alone or in combination, is now an established strategy for treating patients with melanoma and non-small cell lung cancer [57–59]. This evidence concerns the gene CTLA4 and melanoma.